



mgc pharma 

Leading The Way in Phytocannabinoid Derived Medicines

Investor Presentation
2 February 2021


PRESCRIPTION ONLY MEDICINE
KEEP OUT OF REACH OF CHILDREN
mgc pharma 
MXP 100
ORAL DROPS, SOLUTION
100 mg/ml Cannabidiol
30 ml

Corporate Overview

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Shareholder Breakdown



Issued Capital

Ordinary shares	1,788,130,339
Listed Options (\$0.045, expiring 31 August 2021)	85,934,538
Performance Shares and Rights	15,000,000
Unlisted Options (ranging from \$0.05 - \$0.125)	98,400,000

Capital Structure

ASX Code	MXC
Market Capitalisation (as at 27 Jan 2021)	\$50m
Share price	\$0.028
Cash at Bank* (as at 30 September 2020)	\$1.4m




Company Mission

“To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients”

MGC Pharma Total Global Unit Sales – Moving towards break even of 5,000 units / Month

Total Global Units Sold & New Patient Numbers



Board of Directors

Highly qualified team with over 15 years of relevant experience



Roby Zomer

Managing Director, CEO & Co. Founder

Brett Mitchell

Executive Chairman & Co. Founder

Nativ Segev

Non- Executive Director & Founder

Dr. Stephen Parker

Non- Executive Director & Chairman of Audit and Board Committees

Dr. Ross Walker

Non- Executive Director & Head of Medical Advisory Board

Evan Hayes

Non- Executive Director

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.

With over 20 years of experience in the founding, financing and management of both private and publicly listed companies, Mr. Mitchell is responsible for the corporate strategy, capital markets and financial management of the company, and is integrally involved in assisting in building a new industry from the ground up in Australia.

The founder of MGC Pharma, previously CEO of an Israeli licensed Medical Cannabis company, with over 10 years of experience in the global medical cannabis industry and over 15 years of experience in executive roles. Founded MGC Pharma to expand into the International markets and to raise the quality and viability of medicinal phytocannabinoid products.

Dr. Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America, such as the Chairman of Sareum Holdings plc. Dr. Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution.

Dr. Walker is a well-known figure in Australian health, as former host of a weekly radio programme and a prominent cardiologist who specialises in echocardiography and preventative cardiology. Dr. Walker has published several books, and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.

Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours). Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research.



Key Clinical and Operational Management

Leading experts in the medical cannabis space with unparalleled expertise



Nicole Godresse
Global Chief Sales Officer

Nicole has over 20 years' experience in the pharmaceutical/healthcare industry, holding senior roles with major multi-national companies including Eli Lilly, Johnson & Johnson, Schering-Plough, Merck Sharp & Dohme and most recently Tilray. In her most recent roles as General Manager ANZ and Director of Emerging Markets at Tilray, Nicole was instrumental in launching the first Medical Cannabis brand legally in both Australia and New Zealand, launching one of the first Medical Cannabis clinics in Australia, delivering some of Australia's first government funded cannabis clinical trials and negotiating major exclusive government supply agreements.

Dr. Jonathan Grunfeld
Head of Oncology and Palliative Product Development

Certified in Israel, with clinical experience at the MD Anderson Cancer Center, Dr. Grunfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care including direct clinical monitoring of circa 5,000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.

Prof. Emeritus Uri Kramer
Head of Neurology Product Development

Prof Kramer has a busy paediatric epilepsy clinic with many patients being treated with cannabis. Prof Kramer has run full scale epilepsy trials with cannabis and brings a wealth of experience in various fields (Paediatric Neurology & Child Development). Additionally, Prof Kramer is a former president of the Israeli League Against Epilepsy.

Dr. Nadya Lisovoder
Head of Clinical Research (CRO) and Regulatory

15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been a clinical adviser to public biotech companies as well as incubator companies. She has managed clinical trials and has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies.

Amir Polak
Chief Technology Officer

Mr. Polak is a scientist who, for the last 15 years, has been working within the chemical industry in various fields including pharmaceutical, fuel, bio-fuel and 3D printing, from inception through to release to market. Mr. Polak has an MSc in Chemistry from the Hebrew University (Jerusalem).



Company Highlights

MGC Pharma is a European based, vertically integrated bio-pharma company supplying EU-GMP Phytocannabinoid derived products to patients, with increasing product sales in Australia, NZ, UK, Ireland and Brazil through special access schemes, and new key markets opening in EU and Israel



EU-GMP certified manufacturing facility in Europe, manufacturing phytocannabinoid derived medicines – 3 year GMP license granted



Three Investigational Medicinal Products (IMPs) in three clinical trials (Phase II and Phase III)



Additional targeted products in development pipeline with wide IP developments and new Phytotherapeutics line



Rapid growing patient base – delivering affordable cannabinoid medicines to patients. Record quarter of sales & revenue in December 2020 quarter



Global distribution via extensive network of commercial partners and direct patient access in Australia via acquisition of Medicinal Cannabis Clinics



Highly qualified management team, supported by leading clinical advisory experts



Company Strategy

Development and commercialisation of Phytocannabinoid derived products through a vertically integrated, core IP value chain delivering a “Nature to Medicine” business strategy with global distribution capability in place



Genetics

High THC >35% strains
High CBD >20% Strains



Extraction & Isolation into API

Super Critical (Co²)
Alcohol Extraction



Clinical Trials

Europe (EMA)
Australia (TGA)



Product Development

Europe
Australia



Distribution

UK, EU, Australia, NZ
LATAM, MENA



Products



Phytomedicines – Investigational Products



MGC's Phytomedicines are Plant based products proceeding through clinical trails to obtain marketing authorization, which will allow doctors around the world to prescribe a product with accurate claim to treat symptoms



These investigational products allow MGC Pharma to provide prescription and OTC medicines at an affordable price point, in comparison to the alternative treatments for untreated conditions



These products are the outcome of years of experience and development of our medical team, produced under strict GMP guidelines with QA/QC/QP controls and audit



CannEpil® designed as a treatment for refractory epilepsy
CogniCann® designed to improve dementia and Alzheimer's disease patients quality of life



Clinical trials and educational symposiums along side training and patient support platform increasing the access of medicines to the market



MGC Phytotherapeutics Products

Line of EU-GMP certified phytotherapeutic products currently available for prescription by medical professionals under special access schemes



The MGC MP brand of products are non-IMP, providing medical professionals a range of products to prescribe as they see best suited for their patient



This line allows MGC to provide a range of products at a more affordable price point, while maintaining the high-quality EU-GMP certification expected from our patients



The brand, 100% owned by MGC Pharma, includes a suite of products created from the same pipeline used for MGC Pharma IMP products



The product line ranges from pure, whole plant CBD extract, through to a high-THC formulation



It also allows MGC Pharma to grow our patient base, provide white label services, and thus increase our revenues, while maintaining focus on continuing development of our IMPs





Product
Research &
Development



Clinical R&D – Key Products Trials

3 research areas based on medical experience and large data collections. MGC Pharma has commenced the following clinical trials for three of its key Phytomedicine products CannEpil®, CogniCann® and ArtemiC™

Research Areas

Key Products

Neurology

- Epilepsy
- Dementia
- Cerebral Palsy

CannEpil®

Phase IIb Clinical Trial at Schindler Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy

CogniCann®

Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioural benefits CogniCann® may have on patients with dementia and Alzheimer's disease

Autoimmune

- Anti-Inflammatory
- Anti-Bacterial

ArtemiC™

ArtemiC™ does not contain cannabinoids, designed from 4 natural ingredients as a phyto medicine to target viral infections with inflammatory complications. In December 2020 has completed its Phase II Clinical Trail at Nazareth Hospital EMMS, Hillel Yaffe Hospital in Israel and Mahatma Gandhi Mission's Medical College & Hospital in India.

Results from the trial successfully show ArtemiC™ met all its primary and secondary endpoints and statistically significantly improved the clinical recovery of COVID-19 infected patients. ArtemiC™ will now progress to a Phase III Clinical Trial.



CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy

Neurological
Disorders

- Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes
- CannEpil® is an oral oil solution of 20:1 cannabidiol (CBD) and (-)- trans- Δ^9 -tetrahydrocannabinol (THC).
- Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.
- MGC's first pharmaceutical-grade product targeted for drug resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy.
- **Estimated yearly average treatment costs per patient: A\$10,000 – A\$14,000**

Epilepsy

Target Market:

- Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in UK)
- Over 200,000 epilepsy patients in Australia
- Approximately 25% of people with epilepsy have a drug-resistant (DRA) form
- Estimated population at launch of marketing authorisation is over 200,000 people with DRA (in Europe and Australia)
- Expected time to marketing authorisation **4 years**

The global
epilepsy market
is expected to be
~A\$12.9bn
by 2023



As originally announced in November 2019, Company Presentation – UK and Australia Roadshow

Source of target market: [Alacrita Market Projections Report](#); Source of estimated average treatment costs (within the EU): [Alacrita Market Projections Report](#); Source of epilepsy medication market: [Medgadget Market Research Future](#)

CogniCann® is MGC Pharma's second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer's disease patients quality of life

Neurological
Disorders

- Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme
- CogniCann® is a oromucosal spray of cannabidiol (CBD) and (-)- trans-Δ9-tetrahydrocannabinol (THC).
- Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.
- Contains a 3:2 mix of THC (25mg/mL) and CBD (17mg/mL)
- **Estimated yearly average treatment costs per patient : A\$7,800**

Dementia

Target Market:

- Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in UK)
- Over 135,000 mild dementia patients in Australia
- Total estimated with mild dementia population 950,000 at marketing authorisation launch (in Europe and Australia)
- Expected time to marketing authorisation **5 years**

The global dementia medication market is expected to exceed
~A\$40bn
by 2026



As originally announced in November 2019, Company Presentation – UK and Australia Roadshow

Source of target market: [Alacrita Market Projections Report](#); Source of estimated average treatment costs (within the EU): [Alacrita Market Projections Report](#) and Internal Company Evaluation; Source of dementia medication market: [Coherent Market Insights through GlobalNewswire](#)

ArtemiC™ – Successful results from COVID-19 Phase II Clinical Trial

ArtemiC™ is a natural water-soluble food supplement containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C



Powered by:




- ArtemiC™ uses the MyCell Enhanced™ delivery system technology, a patented platform to deliver natural ingredients more effectively in higher concentrations to the cells, improving bioavailability of natural ingredients
- The Phase II human clinical trial testing ArtemiC™ for treatment of COVID-19 included 50 patients across three hospital sites, Nazareth Hospital EMMS, Hillel Yaffe Hospital in Israel and Mahatma Gandhi Mission's Medical College & Hospital in India
- 33 Patients were in the treatment group and 17 patients were in the placebo group
- ArtemiC™ successfully met all its primary and secondary study endpoints (100% of patients in the treatment group), and all FDA requirements for diversity of patients
- ArtemiC™ delivered a NEWS score (main parameter of clinical improvement in COVID-19 patients) of less than or equal to 2 in 100% of patients in the treatment group
- None of the patients in the treatment group required additional oxygen, mechanical ventilation or admission to intensive care
- Results also deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in moderate COVID-19 patients
- Full Trial results are supported by in vitro and in vivo studies and ArtemiC™ will now move to a Phase III clinical trial

ArtemiC™ Clinical Trial Results

100% success in “Time to clinical improvement” based on the national Early Warning Score 2 (NEWS2) of ≤ 2 Maintained for 24 Hours in comparison to routine treatment

NEWS Score 2 is the National Early Warning Score (NEWS), by the FDA, which advocates a system to standardise the assessment and response to acute illness



Study visit	Study group	NEWS Score	P
Before treatment	ArtemiC™	1.5152	0.54
	Placebo	1.8824	
Day 15	ArtemiC™	.5152	0.04
	Placebo	2.2353	



R&D – Preclinical

Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Israel, Europe and Australia. Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals

Neurological

CepaCann Oral Spray to treat Cerebral Palsy

Preclinical in process

Oncological & Cancer Side Effects

Tetrinol Treatment of Anorexia Cachexia in Cancer Patients

Preclinical in process

MXOT01GB01 Treatment of Glioblastoma (NIB Slovenia)

Preclinical in process, Phase I planned H2 2021

MXOT02ME01 Treatment of Melanoma Cancer (RMIT/CannaHub, Aus)

Preclinical in process

MXOT03PC01 Treatment of Prostate Cancer (RMIT/CannaHub, Aus)

Preclinical in process

Autoimmune Disease – Inflammatory

InCann BiActive Capsule to treat Chron's and IBS (RMIT/CannaHub, Aus)

Preclinical in process, Phase I planned H2 2021

TopiCann Topical treatment of Eczema and inflamed skin (Slovenia, EU)

Study Results: 70% Reduction in 4 weeks



Manufacturing, Distribution and Patient Access



EU-GMP Manufacturing Facility



Slovenian EU-GMP certified facility has the capacity to manufacture up to 12,000 prescription products per month – 3 year GMP license granted.




Based on 5,000 units per month, the Company would be at operating cashflow breakeven, excluding Research costs.



Malta facility works commenced following a ~5 million AUD grant for an ArtemiC™ manufacturing facility, construction estimate to complete by June 2021.

Key Global Distribution Partners

Extensive network in place providing access to hospitals, pharmacies and research institutions around the world – Lenis is the Company’s wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets. The Acquisition of Medicinal Cannabis Clinics also provides distribution and direct patient access across Australia



Key Distribution Partners and Patient Access



MGC Pharma completed the acquisition of 100% of the operating telehealth clinic - business assets, data and IP of Medicinal Cannabis Clinics in November 2020, providing an additional operating platform with import and distribution capacity



Supply and distribution agreement with ONIX in Brazil, with minimum order volumes over a minimum seven-year term



Mexacare provides the sales, marketing and logistics for diagnostic devices and complementary medical products to pharmacies, labs, hospitals and doctors in Germany, Austria and Switzerland



Binding term sheet with K.S. KIM International (subsidiary of SK-Pharma Group) for the sales and distribution of ArtemiC™ in Israel, Russia, CIS countries and the Balkan region



Distribution Agreement with Anden Bio Naturals S.A. for the exclusive distribution and commercialisation of MGC products in Peru and Bolivia for a five year period



MGC Products are being access through Early Patient Access Schemes in Brazil, UK, Australia and NZ



Strategic Alliance with Australia's leading epilepsy association, Epilepsy Action Australia

Medicinal Cannabis Clinics – the Next Phase of Growth in Australia

In November 2020, MGC Pharma completed the acquisition of 100% of the operating telehealth clinic - business assets, data and IP of Medicinal Cannabis Clinics (MCC)

About MCC

-  MCC was established in 2019 and is now a leading Australian telehealth medicinal cannabis clinic with an extensive doctor and patient network.
-  MCC has facilitated over 4,000 medical consultations with pre-screened eligible patients.
-  The clinic utilises video telemedicine, allowing its doctors to prescribe the range of cannabinoid medications available in Australia.
-  This transaction provides MGC Pharma with turnkey access to over 600 pharmacy accounts and patients
-  Allow medication to be dispensed and delivered straight to the patient's door.

Strategic synergies providing expedited commercial growth



Acquisition provides MGC Pharma with an operating platform with import and distribution capacity that will significantly expand market access and provide control of the supply chain from manufacturing through to patients.



Allows the Company to improve its profit margins while continuing to provide its high-quality GMP certified medications to at the current affordable prices.



This allows the Company to wholesale and distribute directly to other clinics and pharmacies to reduce storage and distribution costs, while giving the ability to set retail price points.

Investment Proposition

Fully Integrated Model: Research → Product Development → Commercialise

Built on Decades of Experience



Technical team of globally recognised scientists and doctors

Focussed Operations



Core divisions:

- Research and Development
- Manufacturing and Distribution

Strategically Located



Operational bases close to key markets supported by corporate headquarters

Robust Product Offering



Portfolio of established and upcoming products targeting key markets

International Reach



Strong network of research and commercial partners globally

Strong Market Outlook



Global phytocannabinoid market gaining traction



Proposed Placing and Use of Funds

The Company has applied to have its securities traded on the Standard Listing Segment of the London Stock Exchange in addition to its current listing on the ASX. In conjunction with admission to the London market, there is a proposed Placing of new equity to raise approximately £5 million to UK institutional funds and investors.

The Company intends to use the net proceeds of the Placing to:

- meet the costs associated with phase 3 clinical trial ArtemiC™ planned for H1 2021- £2.5m
- meet the costs associated with phase 2b clinical trial in respect of CannEpil®- £1.25m
- increase distribution of the Group's product range and expansion into new markets, including Brazil and EU countries- £0.25m
- meet the registration costs for ArtemiC™ in new markets, including Russia, Middle East and Europe - £0.25m
- General working capital, including funds to complete construction of the Group's proposed manufacturing facilities in Malta - £0.25m.



Disclaimer

IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the following presentation and you are therefore advised to read this disclaimer carefully before reading, assessing or making any other use of the presentation. In accessing the presentation, you agree to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information as a result of such access. You acknowledge that this document and the delivery of the presentation is confidential and intended for you only and you agree you will not forward, distribute, reproduce or publish this document to any other person.

The information contained in these slides and the accompanying verbal presentation (together the “**Presentation**”) is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, “**MGC**”). By accepting this Presentation, you agree to be bound by the following limitations. The content of the Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (as amended) (“**FSMA**”). This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC’s other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

The content of this Presentation has not been approved by an authorised person within the meaning of the FSMA nor by the Financial Conduct Authority or by the London Stock Exchange plc and nor is it intended that it will be so approved. The Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities (including, without limitation, to any person or in any jurisdiction to whom or in which such offer or solicitation is unlawful) nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever or constitute an invitation or inducement to engage in investment activity under section 21 of FSMA.

Notwithstanding the above, this Presentation is only being given to persons reasonably believed by MGC to be in the United Kingdom who are: (1) investment professionals within the meaning of article 19, certified high net worth individuals within the meaning of article 48, high net worth companies within the meaning of article 49, sophisticated investors within the meaning of article 50 and self-certified sophisticated investors within the meaning of article 50A of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended; or (2) "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as amended, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; and (iii) persons who are otherwise permitted by law to receive it (all such persons together being referred to as "relevant persons"). This Presentation is only being sent to persons reasonably believed by MGC to be relevant persons. If you are not such a relevant person (i) you should not have received this Presentation and (ii) please return this Presentation to MGC as soon as possible and take no other action.

Turner Pope Investments (TPI) Limited (“**Turner Pope**”), who is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting only for MGC and is not acting for or advising any other person, or treating any other person (whether or not as a recipient of this Presentation) as its client. Turner Pope will not be responsible for providing regulatory protection afforded to its clients or advice to any other person in relation to the Presentation. Any other person receiving the Presentation should seek their own independent legal, investment and tax advice as they see fit.

The information in this Presentation or on which this Presentation is based has been obtained from sources that MGC believes to be reliable and accurate. However, none of MGC, MGC’s directors, officers, employees, its shareholders or any of their respective advisors, or any other person has independently verified the information in this presentation and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions.



Disclaimer continued

Neither Turner Pope, MGC, nor their respective related bodies corporate, directors, officers, partners, their advisers, agents and/or employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

The Presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or used for any other purpose. By accepting delivery of this Presentation, each recipient agrees to treat this Presentation as strictly confidential and not to reproduce, distribute or otherwise use this Presentation or any of its contents without the prior written consent of MGC.

The information in this Presentation is for general information only. To the extent that certain statements contained in this presentation may constitute “forward-looking statements” or statements about “future matters”, the information reflects MGC’s intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation may not be distributed, published, reproduced or otherwise made available to any other person, in whole or in part, for any purposes whatsoever. In particular, it should not be distributed to or otherwise made available to persons with addresses in Canada, Japan, the Republic of South Africa or the United States, its territories or possessions or in any other jurisdiction outside of the United Kingdom or Australia where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting this Presentation, you agree to be bound by the provisions, the limitations and conditions set out in this disclaimer and, in particular, you have represented, warranted and undertaken that: (i) you are a Relevant Person and you will observe the foregoing provisions, limitations and conditions, (ii) you have read and agree to comply with the contents of this disclaimer; and (iii) you agree to keep permanently confidential the information contained in the Presentation or made available in connection with further enquiries to the extent such information is not made publicly available (otherwise through a breach by you of this provision).

AN INVESTMENT IN MGC INVOLVES RISK. SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF MGC TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE PREDICTED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, THE ACTUAL RESULTS OF MGC MAY VARY MATERIALLY FROM THOSE FORECASTED IN THIS PRESENTATION.



mgc pharma



<https://mgcpharma.com.au/>



@mgcpharmaceuticals



@MGC_Pharma



MGC Pharmaceuticals Ltd

Australian PR/IR - Media and Capital Partners

Rod Hinchcliffe +61 412 277 377

rod.hinchcliffe@mcpartners.com.au

UK PR – Tavistock

Charles Vivian +44 20 7920 3150

Charles.Vivian@tavistock.co.uk